值此盛会,北京大学肿瘤医院盛锡楠教授公布了一项II期RC48-C017研究的初步疗效和安全性结果,提示维迪西妥单抗+特瑞普利单抗新辅助联合治疗方案在HER2有表达的肌层浸润性膀胱癌(MIBC)患者中有希望的治疗潜力1,医脉通带您领略其中精彩内容...
Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients ... X Sheng,K Yang,Y Ji,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2024年 Results of an Ongoing Phase 2 Study of Brentuxima...
Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression.doi:10.1200/JCO.2024.42.16_suppl.4568...